UBS Oncology Impact Fund L.P. is 10% Owner at Harpoon Therapeutics, Inc. (HARP). They have made 4 open-market trades across 2 companies since 2019, most recently 2025-12-01.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| HOWL | SELL · 10b5-1 | 2025-11-26 | 2025-12-01 | $0.96 | $137K | +21.1% | -29.6% | -35.2% |
| HOWL | SELL · 10b5-1 | 2025-11-07 | 2025-11-12 | $1.13 | $241K | -8.7% | +2.8% | -32.9% |
| HOWL | SELL · 10b5-1 | 2025-10-27 | 2025-10-29 | $1.68 | $238K | -25.2% | -35.5% | -56.7% |
| ITOS | SELL | 2021-09-23 | 2021-09-27 | $27.65 | $3.2M | -1.7% | +0.4% | +73.5% |
| CGEM | SELL · 10b5-1 | 2021-08-31 | 2021-09-02 | $29.50 | $717K | -0.9% | -21.6% | -43.4% |
| HARP | SELL | 2021-05-21 | 2021-05-24 | $20.19 | $541K | -17.4% | -21.5% | -52.5% |
| HARP | SELL | 2021-04-09 | 2021-04-13 | $21.94 | $1.2M | +3.8% | +0.1% | -33.0% |
| HARP | SELL | 2019-02-12 | 2019-02-14 | $14.00 | $6K | +5.1% | -14.7% | -29.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.